Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment.

ABSTRACT:

Introduction

Limited comparative effectiveness data for rituximab (RTX) versus natalizumab (NTZ), fingolimod (FTY), and dimethyl fumarate (DMF) for the treatment of multiple sclerosis (MS) exist.

Methods

Clinician-reported data on patients prescribed RTX, NTZ, FTY, or DMF for the treatment of MS at the Rocky Mountain MS Center at the University of Colorado were retrospectively collected. Outcomes included a composite effectiveness measure consisting of clinical relapse, contrast-enhancing lesions, and/or new T2 lesions, individual effectiveness outcomes, and discontinuation. Logistic regression was used on patients matched by propensity scores and using average treatment effect on treated doubly robust weighting estimator.

Results

A total of 182, 451, 271, and 342 pat

SUBMITTER: Vollmer BL 

PROVIDER: S-EPMC7480919 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature